Loading
A planned early study of KH815 in people with advanced solid tumors. The registry still lists it as not yet recruiting, with no results posted.
NCT06885645 is a first-in-human dose-escalation study of the dual-payload TROP2 ADC KH815. The ClinicalTrials.gov record last posted 3 April 2025 lists NOT_YET_RECRUITING, estimated enrollment of 30, an estimated start on 30 April 2025 and estimated primary completion on 30 June 2027. These dates remain estimates when checked 6 October 2026; no results or study locations are posted. The protocol excludes a history of interstitial lung disease/pneumonia or screening imaging on which it cannot be ruled out. Registered status does not confirm current availability or individual eligibility.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/